2.71

18.86% 0.43

After Hours: 2.56 -0.15 -5.54%

Lexeo Therapeutics Inc (LXEO)

Overview News Price History Financials Discussions Forecast

Lexeo Therapeutics Inc stock is traded at $2.71, with a volume of 608.28K. It is up +18.86% in the last 24 hours and down -12.86% over the past month. Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.

Previous Close:

$2.28

Open:

$2.26

24h Volume:

608.28K

Relative Volume:

0.91

Market Cap:

$71.04M

Revenue:

Net Income/Loss:

$-86.60M

P/E Ratio:

-0.9568

EPS:

-2.8324

Net Cash Flow:

$-67.37M

1W Performance:

+24.88%

1M Performance:

-12.86%

6M Performance:

-70.22%

1Y Performance:

-77.90%

1-Day Range:

$2.25

$2.73

1-Week Range:

$1.895

$2.73

52-Week Range:

$1.45

$19.50

Lexeo Therapeutics Inc Stock (LXEO) Company Profile

Name

Lexeo Therapeutics Inc

Sector

Healthcare (1151)

Industry

Biotechnology (660)

Phone

(212) 547-9879

Address

345 PARK AVENUE SOUTH, NEW YORK

Employee

Twitter

Next Earnings Date

2025-03-24

Latest SEC Filings

LXEO's Discussions on Twitter

Compare LXEO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LXEO Lexeo Therapeutics Inc	2.71	71.04M	0	-86.60M	-67.37M	-2.8324
VRTX Vertex Pharmaceuticals Inc	489.10	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	563.16	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	596.20	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	234.56	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	230.98	26.16B	3.81B	-644.79M	-669.77M	-6.24

Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-13-24	Initiated	Robert W. Baird	Outperform
Jun-06-24	Initiated	H.C. Wainwright	Buy
Nov-28-23	Initiated	Chardan Capital Markets	Buy
Nov-28-23	Initiated	JP Morgan	Overweight
Nov-28-23	Initiated	Leerink Partners	Outperform
Nov-28-23	Initiated	RBC Capital Mkts	Outperform
Nov-28-23	Initiated	Stifel	Buy

View All

Lexeo Therapeutics Inc Stock (LXEO) Latest News

Apr 12, 2025

Chardan Capital Has Positive Outlook of LXEO FY2025 Earnings - Defense World

Apr 12, 2025

Apr 11, 2025

Lexeo Therapeutics: Promising Cardiovascular Gene Therapy Pipeline and Strong Financial Position Justify Buy Rating - TipRanks

Apr 11, 2025

Apr 10, 2025

Lexeo’s Gene Therapy LX2006 Reduces Abnormal LVMI in Patients With Friedreich Ataxia Cardiomyopathy - CGTLive®

Apr 10, 2025

Gene Therapy Shows Promise for Fatal Heart Condition Tied to Friedreich Ataxia - Managed Healthcare Executive

Apr 10, 2025

Promising Therapeutic Advancements and Strategic Progression Support Buy Rating for Lexeo Therapeutics, Inc. - TipRanks

Apr 10, 2025

Apr 08, 2025

Chardan Research Adjusts Lexeo Therapeutics Price Target to $22 From $25, Maintains Buy Rating - MarketScreener

Apr 08, 2025

Lexeo’s Cardiac Gene Therapy Achieves Good Early Trial Results - Inside Precision Medicine

Apr 08, 2025

Lexeo Plots Pivotal Path for Friedreich’s Ataxia Gene Therapy After ‘Compelling’ Phase I/II Data - BioSpace

Apr 08, 2025

H.C. Wainwright maintains Buy rating on Lexeo Therapeutics stock - Investing.com

Apr 08, 2025

H.C. Wainwright maintains Buy rating on Lexeo Therapeutics stock By Investing.com - Investing.com UK

Apr 08, 2025

Apr 07, 2025

Lexeo Therapeutics price target lowered to $22 from $25 at Chardan - TipRanks

Apr 07, 2025

Lexeo touts Friedreich ataxia cardiomyopathy candidate as 'best-in-class' - FirstWord Pharma

Apr 07, 2025

Lexeo Therapeutics Reports Positive Interim Trial Results - TipRanks

Apr 07, 2025

Lexeo discloses new data for heart drug; Spark Therapeutics to lay off workers - Endpoints News

Apr 07, 2025

Lexeo Therapeutics Says Potential FA Cardiomyopathy Therapy Improves Cardiac Biomarkers - MarketScreener

Apr 07, 2025

Lexeo Therapeutics announces ‘positive’ Interim Phase 1/2 data for LX2006 - TipRanks

Apr 07, 2025

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data For Lx2006 In Friedreich Ataxia Cardiomyopathy Supporting Advancement To Registrational Study - MarketScreener

Apr 07, 2025

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study - GlobeNewswire

Apr 07, 2025

Breakthrough Data: Gene Therapy Shows 25% Heart Improvement in Fatal Rare Disease - Stock Titan

Apr 07, 2025

Apr 05, 2025

Lexeo stock hits 52-week low at $2.31 amid sharp annual decline - Investing.com Canada

Apr 05, 2025

Apr 04, 2025

Lexeo stock hits 52-week low at $2.31 amid sharp annual decline By Investing.com - Investing.com South Africa

Apr 04, 2025

Apr 02, 2025

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Rating of “Buy” by Brokerages - Defense World

Apr 02, 2025

Mar 31, 2025

Cell, gene therapy makers lose a champion at FDA with exit of Peter Marks - BioPharma Dive

Mar 31, 2025

Mar 30, 2025

Q1 EPS Estimate for Lexeo Therapeutics Raised by Analyst - The AM Reporter

Mar 30, 2025

Mar 29, 2025

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Stock Holdings Raised by Bank of New York Mellon Corp - Defense World

Mar 29, 2025

HC Wainwright Reaffirms Buy Rating for Lexeo Therapeutics (NASDAQ:LXEO) - Defense World

Mar 28, 2025

Mar 27, 2025

Lexeo Therapeutics Sees Biggest Retail Follower Surge Among Biotech Stocks After Record-Breaking Rally: What's The Big Draw? - MSN

Mar 27, 2025

Analysts Offer Predictions for LXEO Q1 Earnings - Defense World

Mar 27, 2025

Mar 26, 2025

Lexeo Therapeutics (NASDAQ:LXEO) Price Target Lowered to $20.00 at Royal Bank of Canada - Defense World

Mar 26, 2025

2 Stocks Riding the Biotech Surge With Major Catalysts Ahead - Investing.com

Mar 26, 2025

H.C. Wainwright maintains Buy on Lexeo stock, $23 target By Investing.com - Investing.com Canada

Mar 26, 2025

Lexeo Therapeutics (NASDAQ:LXEO) Receives “Buy” Rating from Chardan Capital - Defense World

Mar 26, 2025

H.C. Wainwright maintains Buy on Lexeo stock, $23 target - Investing.com

Mar 26, 2025

Mar 25, 2025

Lexeo Therapeutics price target lowered to $20 from $24 at RBC Capital - TipRanks

Mar 25, 2025

Pharma Frenzy: Volatility Ignites Biotech Sector - Sharewise

Mar 25, 2025

Why Lexeo Therapeutics (LXEO) Skyrocketed on Monday? - MSN

Mar 25, 2025

RBC Cuts Price Target on Lexeo Therapeutics to $20 From $24, Keeps Outperform, Speculative Risk - MarketScreener

Mar 25, 2025

Lexeo Therapeutics Sees Biggest Retail Follower Surge Among Biotech Stocks After Record-Breaking Rally: What's - Asianet Newsable

Mar 25, 2025

Lexeo Therapeutics (NASDAQ:LXEO) Price Target Cut to $18.00 by Analysts at Leerink Partners - Defense World

Mar 25, 2025

Lexeo Therapeutics Advances Genetic Medicine Initiatives - TipRanks

Mar 25, 2025

Mar 24, 2025

10 Small Firms Kick Off Monday with Strong Gains - Insider Monkey

Mar 24, 2025

Leerink cuts Lexeo Therapeutics price target to $18, maintains Outperform By Investing.com - Investing.com Canada

Mar 24, 2025

Leerink cuts Lexeo Therapeutics price target to $18, maintains Outperform - Investing.com

Mar 24, 2025

Lexeo Therapeutics stock soars 40% on positive trial data By Investing.com - Investing.com South Africa

Mar 24, 2025

Lexeo Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - MarketScreener

Mar 24, 2025

SEC Form 424B5 filed by Lexeo Therapeutics Inc. - Quantisnow

Mar 24, 2025

Lexeo Therapeutics May Offer And Sell Shares Of Common Stock Of Up To $75 MillionSEC Filing - Marketscreener.com

Mar 24, 2025